Zacks: Brokerages Anticipate Merus (NASDAQ:MRUS) Will Announce Earnings of -$0.65 Per Share

Analysts predict that Merus (NASDAQ:MRUSGet Rating) will post earnings of ($0.65) per share for the current quarter, according to Zacks. Five analysts have made estimates for Merus’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.80). Merus reported earnings per share of ($0.71) during the same quarter last year, which suggests a positive year over year growth rate of 8.5%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Merus will report full-year earnings of ($2.48) per share for the current year, with EPS estimates ranging from ($3.17) to ($2.04). For the next financial year, analysts expect that the company will post earnings of ($2.62) per share, with EPS estimates ranging from ($3.53) to ($1.38). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Merus.

Merus (NASDAQ:MRUSGet Rating) last issued its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.24. The business had revenue of $14.71 million for the quarter, compared to the consensus estimate of $12.39 million. Merus had a negative net margin of 143.77% and a negative return on equity of 29.02%.

A number of research analysts recently commented on MRUS shares. BMO Capital Markets started coverage on shares of Merus in a report on Friday, February 11th. They issued an “outperform” rating and a $45.00 price target for the company. Zacks Investment Research raised shares of Merus from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Friday, May 13th. HC Wainwright reaffirmed a “buy” rating on shares of Merus in a research note on Tuesday, May 10th. StockNews.com began coverage on shares of Merus in a report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, Needham & Company LLC started coverage on shares of Merus in a report on Thursday, February 10th. They set a “buy” rating and a $45.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $37.78.

In other news, EVP Peter B. Silverman sold 60,000 shares of the firm’s stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $26.95, for a total value of $1,617,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.90% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. UBS Group AG raised its position in Merus by 15.8% during the third quarter. UBS Group AG now owns 3,299 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 449 shares during the last quarter. Vanguard Group Inc. grew its stake in Merus by 0.5% during the first quarter. Vanguard Group Inc. now owns 120,889 shares of the biotechnology company’s stock worth $3,196,000 after buying an additional 638 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Merus by 53.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,825 shares of the biotechnology company’s stock worth $75,000 after buying an additional 989 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Merus by 10.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,267 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 1,104 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Merus by 22.1% during the fourth quarter. Legal & General Group Plc now owns 6,627 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.

Shares of MRUS stock traded down $0.47 during trading hours on Thursday, hitting $15.81. The stock had a trading volume of 209,488 shares, compared to its average volume of 312,817. Merus has a one year low of $14.78 and a one year high of $33.09. The stock’s 50-day moving average price is $23.65 and its two-hundred day moving average price is $26.31. The stock has a market capitalization of $688.53 million, a price-to-earnings ratio of -8.45 and a beta of 1.11.

About Merus (Get Rating)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Further Reading

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.